T2DM: KOL Insight

T2DM: KOL Insight

Contents

Report Overview >

Pipeline Programmes >

Marketed Therapies >

KOLs Interviewed >

Methodology >

Research Objectives >

Ongoing Benefits >

2

T2DM: KOL Insight

Report Overview

Instead of asking KOLs generic questions about the strengths and weaknesses of current and pipeline therapies, Therapy Trends analysts focus the research on the key battlegrounds for market share, i.e. the emphasis is on segments of the market which are likely to have the greatest impact going forward.

We are able to spend more time asking very in-depth questions about specific products ensuring more valuable insights are generated.

3

T2DM: KOL Insight

Pipeline Therapies

Efficacy

Tolerability

Safety

Key Trials to Watch

At-a-glance view of key data on late-stage pipeline therapies. For most of the programmes listed below, the report includes tables covering:

GLP-1 agonists Semaglutide franchise (oral & once weekly injectable formulations; Novo Nordisk) ITCA 650 (exenatide; Intarcia Therapeutics) SGLT-2 inhibitor Ertugliflozin (PF04971729; Pfizer/Merck & Co.)

Basal insulin NN1218/FIAsp (insulin aspart; Novo Nordisk) Basal insulin/GLP-1 agonist LixiLan (lixisenatide/Insulin glargine; Sanofi)

4

T2DM: KOL Insight

Commercial Profile

Efficacy

Tolerability

Safety

At-a-glance view of key data on approved and off-label therapies. For each therapy listed below, the report includes tables covering:

GLP-1 agonists Lyxumia/Adlynx (lixisenatide; Sanofi) Tanzeum/ Eperzan (albiglutide; GSK)

Trulicity (delaglutide; Eli Lilly) DPP-4 inhibitors Onglyza (saxagliptin; AstraZeneca) Nesina/Vipidia (alogliptin; Takeda) Tradjenta/Trajenta (linagliptin; Boehringer Ingelheim) Zafatek (trelagliptin; Takeda/Furiex)

SGLT-2 inhibitor Farxiga/Forxiga (dapagliflozin; AstraZeneca/ Bristol-Myers Squibb) Invokana (canagliflozin; Johnson & Johnson)

Jardiance (empagliflozin; Boehringer Ingelheim)

Insulins Tresiba (insulin degludec; Novo Nordisk) Toujeo/Optisulin (insulin glargine; Sanofi) Abasaglar/Basaglar (insulin glargine biosimilar; Eli Lilly/Boehringer Ingelheim)

Fixed Dose Combinations (FDCs) Synjardy (empagliflozin/metformin [SGLT-2i/Biguanide]; Boehringer Ingelheim) Qtern/SaxaDapa (saxagliptin/dapagliflozin [SGLT-

2i/DPP-4i]; AstraZeneca) Glyxambi (empagliflozin/linagliptin [SGLT-2i /DPP-4i]; Boehringer Ingelheim/Eli Lilly) Xultophy/IDegLira (insulin degludec/liraglutide [insulin/GLP-1 agonist]; Novo Nordisk) Ryzodeg (insulin degludec/insulin aspart [recombinant human insulin]; Novo Nordisk)

Marketed Therapies

5

T2DM: KOL Insight

KOLs from EU

KOLs Interviewed

KOLs from North America Professor Antonio Ceriello, MD. Head of the Research

Department on Diabetes and CVD, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.

Jens Holst, MD, PhD. Professor of medical physiology, University of Copenhagen, Denmark.

Bernard Charbonnel, MD. Professor of Endocrinology and Metabolic Diseases, University of Nantes, France.

Prof. Marc Y. Donath. Professor for Endocrinology, Head of the Clinic for Endocrinology, Diabetes and Metabolism at the University Hospital of Basel, Switzerland.

Prof. David Matthews, MA (Oxon), DPhil, BM, BCh, FRCP. Professor of Diabetes Medicine, University of Oxford, and Medical Tutor & Dean at Harris Manchester College, Oxford, UK.

German KOL (Anonymous). Professor and head of Clinical Research in Diabetes at a leading university hospital in Germany.

6

Jay S. Skyler, MD, MACP. Professor of Medicine, Paediatrics and Psychology and Deputy Director, Clinical Research and Academic Programmes, Diabetes Research Institute, University of Miami Miller School of Medicine.

Etie Moghissi, MD, FACP, FACE. Associate Clinical Professor of Medicine, UCLA David Geffen School of Medicine and Consultant in Diabetes, Endocrinology and Metabolism in Marina del Rey California, USA.

John E. Anderson, MD. Past President, Medicine & Science, American Diabetes Association (ADA), USA.

George Grunberger, MD, FACP, FACE. Chairman, Grunberger Diabetes Institute (GDI) in Bloomfield Hills, Michigan, USA.

Dr. Silvio Inzucchi MD. Professor of Medicine, Yale University School of Medicine, New Haven, USA.

Prof. Carol Wysham, MD. Research Professor, Washington State University & Assistant Clinical Professor of Medicine, University of Washington School of Medicine, USA.

T2DM: KOL Insight

Methodology

Secondary Research

Detailed analysis of key marketed products and pipeline programmes, including key clinical data and trials

Primary Research

Interviews with 12 of the world’s foremost KOLs

Analysis

A balanced and independent qualitative review which clearly presents the factors impacting current and future product positioning and competitiveness

7

T2DM: KOL Insight

Methodology

Secondary Research:

Analysis of key clinical data and ongoing trials enables the analyst to develop a robust understanding of each drug and develop research objectives which will answer important business questions about current and future product positioning and competitiveness.

8

T2DM: KOL Insight

Methodology

Primary Research:

The KOLs are selected based on criteria which ensure we are getting feedback from the most influential leaders in the field of T2DM such as:

• greater than 10 years experience in the field

• greater than 30 percent of their time is spent treating patients

• greater than 10 papers published in peer reviewed journals in the last 5 years

• lead or principal investigator on clinical trials within last 5 years

• has presented at major conferences at least 3 times in last 5 years

• has recently served or currently serves as reviewer for peer reviewed scientific journals

9

T2DM: KOL Insight

Methodology

In-depth secondary research and (where appropriate) preparatory discussions with KOLs allows the analyst to develop the research objectives and discussion guide to ensure the research will gain valuable insights from KOLs and answer important business questions.

The analyst interviewing KOLs constantly monitors the market, is aware of the latest news/data and has a track record of gaining valuable insights from KOLs.

Analysis:

Therapy Trends analysts review the interview transcripts and present an organised and balanced view of KOL opinions, adding clarity to complex issues.

10

T2DM: KOL Insight

Research Objectives

• Analysis of product attributes which confer preferred status

• Product perception by the medical community

• Clinical trials with greatest potential to impact prescribing trends

• Therapy attributes needed to become the treatment of choice

• The future role and potential impact of current and late-stage pipeline therapies

• Mapping the future evolution of the treatment landscape

11

T2DM: KOL Insight

Ongoing Benefits

PLUS – 3 quarterly updates on the treatment landscape:

FirstWord provides regular update bulletins in a disease area following the publication of a related Therapy Trends KOL Insight report. FirstWord analysts constantly monitor the market and at regular intervals obtain the reactions of KOLs to significant events, such as marketing approvals or the results of pivotal clinical trials. This continuous monitoring and frequent engagement with experts provides timely access to the strategic insights that support critical business decisions.

Buy online now

12